Evangelos J Giamarellos-Bourboulis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9437819/publications.pdf

Version: 2024-02-01

435 papers

24,603 citations

69 h-index 136 g-index

474 all docs

474 docs citations

times ranked

474

30783 citing authors

#	Article	IF	Citations
1	A four-probiotic preparation for ventilator-associated pneumonia in multi-trauma patients: results of a randomized clinical trial. International Journal of Antimicrobial Agents, 2022, 59, 106471.	2.5	21
2	ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically III COVID-19 Patients. Journal of Innate Immunity, 2022, 14, 218-228.	3.8	21
3	Meropenem-vaborbactam: a critical positioning for the management of infections by Carbapenem-resistant <i>Enterobacteriaceae</i> . Expert Review of Anti-Infective Therapy, 2022, 20, 809-818.	4.4	3
4	A 6-mRNA host response classifier in whole blood predicts outcomes in COVID-19 and other acute viral infections. Scientific Reports, 2022, 12, 889.	3.3	15
5	A guide to immunotherapy for COVID-19. Nature Medicine, 2022, 28, 39-50.	30.7	206
6	Reply to: â€~Lack of evidence for intergenerational inheritance of immune resistance to infections'. Nature Immunology, 2022, 23, 208-209.	14.5	9
7	High levels of monocytic myeloid-derived suppressor cells are associated with favorable outcome in patients with pneumonia and sepsis with multi-organ failure. Intensive Care Medicine Experimental, 2022, 10, 5.	1.9	13
8	Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure. Cell Reports Medicine, 2022, 3, 100560.	6.5	23
9	Identification of clinical features affecting diagnostic delay in paediatric hidradenitis suppurativa: results from a multicentre observational study. British Journal of Dermatology, 2022, 187, 428-430.	1.5	6
10	Antimicrobial Stewardship Using Biomarkers: Accumulating Evidence for the Critically Ill. Antibiotics, 2022, 11, 367.	3.7	9
11	An animal model of limitation of gut colonization by carbapenemase-producing Klebsiella pneumoniae using rifaximin. Scientific Reports, 2022, 12, 3789.	3.3	3
12	Heparin Binding Protein for the Early Diagnosis and Prognosis of Sepsis in the Emergency Department: The Prompt Multicenter Study. Shock, 2022, 57, 518-525.	2.1	17
13	Calprotectin and Imbalances between Acute-Phase Mediators Are Associated with Critical Illness in COVID-19. International Journal of Molecular Sciences, 2022, 23, 4894.	4.1	17
14	IL-1 Mediates Tissue-Specific Inflammation and Severe Respiratory Failure in COVID-19. Journal of Innate Immunity, 2022, 14, 643-656.	3.8	18
15	Small Intestine Bacterial Overgrowth Can Form an Indigenous Proinflammatory Environment in the Duodenum: A Prospective Study. Microorganisms, 2022, 10, 960.	3.6	5
16	Personalised immunotherapy in sepsis: a scoping review protocol. BMJ Open, 2022, 12, e060411.	1.9	4
17	Redefining critical illness. Nature Medicine, 2022, 28, 1141-1148.	30.7	136
18	Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial. Critical Care, 2022, 26, .	5.8	14

#	Article	IF	Citations
19	A Four-Probiotic Regime to Reduce Surgical Site Infections in Multi-Trauma Patients. Nutrients, 2022, 14, 2620.	4.1	6
20	High Prevalence of Small Intestinal Bacterial Overgrowth among Functional Dyspepsia Patients. Digestive Diseases, 2021, 39, 382-390.	1.9	14
21	MABp1 targeting interleukinâ€1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the openâ€label extension period. Clinical and Experimental Dermatology, 2021, 46, 162-163.	1.3	14
22	Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 202-210.	5.6	71
23	Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes. Journal of Infectious Diseases, 2021, 223, 214-224.	4.0	86
24	Diabetes on sepsis outcomes in non-ICU patients: A cohort study and review of the literature. Journal of Diabetes and Its Complications, 2021, 35, 107765.	2.3	9
25	Monitoring immunomodulation in patients with sepsis. Expert Review of Molecular Diagnostics, 2021, 21, 17-29.	3.1	6
26	Transcriptomic similarities and differences in host response between SARS-CoV-2 and other viral infections. IScience, 2021, 24, 101947.	4.1	70
27	Biomarkers in sepsis: can they help improve patient outcome?. Current Opinion in Infectious Diseases, 2021, 34, 126-134.	3.1	7
28	Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. Genome Medicine, 2021, 13, 7.	8.2	193
29	Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19. Journal of Infectious Diseases, 2021, 223, 1322-1333.	4.0	61
30	The Association of TSH and Thyroid Hormones With Lymphopenia in Bacterial Sepsis and COVID-19. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1994-2009.	3.6	15
31	Management of superficial and deep surgical site infection: an international multidisciplinary consensus. Updates in Surgery, 2021, 73, 1315-1325.	2.0	8
32	An open label trial of anakinra to prevent respiratory failure in COVID-19. ELife, 2021, 10, .	6.0	127
33	Host cystathionine- \hat{l}^3 lyase derived hydrogen sulfide protects against Pseudomonas aeruginosa sepsis. PLoS Pathogens, 2021, 17, e1009473.	4.7	12
34	Infective Endocarditis in Patients on Chronic Hemodialysis. Journal of the American College of Cardiology, 2021, 77, 1629-1640.	2.8	23
35	Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. EBioMedicine, 2021, 66, 103291.	6.1	15
36	Multi-cohort analysis of host immune response identifies conserved protective and detrimental modules associated with severity across viruses. Immunity, 2021, 54, 753-768.e5.	14.3	42

#	Article	IF	Citations
37	The authors reply. Critical Care Medicine, 2021, Publish Ahead of Print, e720-e721.	0.9	O
38	Neutrophil trafficking: the missing link in the pathogenesis of hidradenitis suppurativa. British Journal of Dermatology, 2021, 185, 15-16.	1.5	0
39	Immunomodulation Through Beta-D-glucan in Chemically-induced Necrotizing Pancreatitis. Journal of Surgical Research, 2021, 261, 74-84.	1.6	1
40	Evolution of epidemiological characteristics of infective endocarditis in Greece. International Journal of Infectious Diseases, 2021, 106, 213-220.	3.3	6
41	Swarm Learning for decentralized and confidential clinical machine learning. Nature, 2021, 594, 265-270.	27.8	375
42	Leukocyte Activation Profile Assessed by Raman Spectroscopy Helps Diagnosing Infection and Sepsis. , 2021, 3, e0394.		17
43	Differential response induced by LPS and MPLA in immunocompetent and septic individuals. Clinical Immunology, 2021, 226, 108714.	3.2	9
44	BioFire® FilmArray® Pneumonia Panel for Severe Lower Respiratory Tract Infections: Subgroup Analysis of a Randomized Clinical Trial. Infectious Diseases and Therapy, 2021, 10, 1437-1449.	4.0	18
45	Target molecules for future hidradenitis suppurativa treatment. Experimental Dermatology, 2021, 30, 8-17.	2.9	34
46	The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19): A Position Paper by Four Medical Societies from Greece. Infectious Diseases and Therapy, 2021, 10, 1081-1095.	4.0	2
47	A 29-mRNA host response test from blood accurately distinguishes bacterial and viral infections among emergency department patients. Intensive Care Medicine Experimental, 2021, 9, 31.	1.9	12
48	Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19. European Journal of Internal Medicine, 2021, 88, 52-62.	2.2	14
49	Antiâ€COVIDâ€19 measurements for hidradenitis suppurativa patients. Experimental Dermatology, 2021, 30, 18-22.	2.9	12
50	The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respiratory Medicine, the, 2021, 9, 622-642.	10.7	371
51	Cytokine production and outcome in MDR <i>versus</i> non-MDR gram-negative bacteraemia and sepsis. Infectious Diseases, 2021, 53, 764-771.	2.8	7
52	Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis*. Critical Care Medicine, 2021, 49, 2042-2057.	0.9	88
53	Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19. Journal of Clinical Medicine, 2021, 10, 3907.	2.4	17
54	The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. Journal of the American Academy of Dermatology, 2021, 85, 369-378.	1.2	46

#	Article	IF	CITATIONS
55	Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial. Infectious Diseases and Therapy, 2021, 10, 2333-2351.	4.0	14
56	Treatment with IgM-enriched immunoglobulin in sepsis: a matched case-control analysis. Journal of Critical Care, 2021, 64, 120-124.	2.2	8
57	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nature Medicine, 2021, 27, 1752-1760.	30.7	353
58	Efficacy of tigecycline alone or in combination for experimental infections by KPC carbapenemase-producing Klebsiella pneumoniae. International Journal of Antimicrobial Agents, 2021, 58, 106384.	2.5	3
59	Biochemical Analysis of Leukocytes after In Vitro and In Vivo Activation with Bacterial and Fungal Pathogens Using Raman Spectroscopy. International Journal of Molecular Sciences, 2021, 22, 10481.	4.1	12
60	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatology, The, 2021, 3, e690-e697.	3.9	121
61	Integration of heparin-binding protein and interleukin-6 in the early prediction of respiratory failure and mortality in pneumonia by SARS-CoV-2 (COVID-19). European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1405-1412.	2.9	19
62	Complex Immune Dysregulation in COVID-19 and Implications for Treatment. Annual Update in Intensive Care and Emergency Medicine, 2021, , 15-24.	0.2	0
63	<i>Staphylococcus aureus</i> Carriage in Hidradenitis Suppurativa: Impact on Response to Adalimumab. Dermatology, 2021, 237, 372-377.	2.1	3
64	Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study. In Vivo, 2021, 35, 653-661.	1.3	22
65	Validation of Inflammopathic, Adaptive, and Coagulopathic Sepsis Endotypes in Coronavirus Disease 2019. Critical Care Medicine, 2021, 49, e170-e178.	0.9	26
66	Transmission of trained immunity and heterologous resistance to infections across generations. Nature Immunology, 2021, 22, 1382-1390.	14.5	72
67	Complex immune deregulation in severe COVID-19: More than a mechanism of pathogenesis. EBioMedicine, 2021, 73, 103673.	6.1	6
68	Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials. Journal of Clinical Medicine, 2021, 10, 5366.	2.4	4
69	Soluble fms-like tyrosine kinase 1, placental growth factor and procalcitonin as biomarkers of gram-negative sepsis. Medicine (United States), 2021, 100, e27662.	1.0	0
70	Angiotensinâ€Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVIDâ€19. Journal of the American Heart Association, 2021, 10, e023535.	3.7	15
71	Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. Journal of the American Academy of Dermatology, 2020, 82, 366-376.	1.2	165
72	Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study. International Journal of Antimicrobial Agents, 2020, 55, 105836.	2.5	10

#	Article	IF	CITATIONS
73	Association of modulation of proâ€inflammatory responses by dectinâ€2 with preterm delivery: An experimental model. American Journal of Reproductive Immunology, 2020, 83, e13216.	1.2	1
74	Soluble Urokinase Receptor (SuPAR) in COVID-19–Related AKI. Journal of the American Society of Nephrology: JASN, 2020, 31, 2725-2735.	6.1	93
75	Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly. Cell, 2020, 183, 315-323.e9.	28.9	279
76	Safety and COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort Study. Cell Reports Medicine, 2020, 1, 100073.	6.5	78
77	What causes hidradenitis suppurativa ?—15 years after. Experimental Dermatology, 2020, 29, 1154-1170.	2.9	90
78	Comparability of Raman Spectroscopic Configurations: A Large Scale Cross-Laboratory Study. Analytical Chemistry, 2020, 92, 15745-15756.	6.5	46
79	A novel optical biosensor for the early diagnosis of sepsis and severe Covid-19: the PROUD study. BMC Infectious Diseases, 2020, 20, 860.	2.9	7
80	Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. Anaesthesia, Critical Care & Description (2020), 39, 723-730.	1.4	22
81	Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Coronavirus. Shock, 2020, 54, 633-637.	2.1	68
82	SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. Shock, 2020, 54, 416-437.	2.1	41
83	Transcriptional and functional insights into the host immune response against the emerging fungal pathogen Candida auris. Nature Microbiology, 2020, 5, 1516-1531.	13.3	75
84	Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. Cell, 2020, 181, 969-977.	28.9	358
85	Growth on Carbohydrates from Carbonaceous Meteorites Alters the Immunogenicity of Environment-Derived Bacterial Pathogens. Astrobiology, 2020, 20, 1353-1362.	3.0	3
86	Gut Microbiota Dysbiosis in Functional Dyspepsia. Microorganisms, 2020, 8, 691.	3.6	36
87	Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group. Infectious Diseases and Therapy, 2020, 9, 407-416.	4.0	17
88	Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis. Cell Host and Microbe, 2020, 28, 117-123.e1.	11.0	210
89	Further evidence for the immediate knowledge improvement through EADV Schools on hidradenitis suppurativa/acne inversa. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e852-e853.	2.4	3
90	The interplay between acute bacterial skin and skin structure infections and depression. Current Opinion in Infectious Diseases, 2020, 33, 1 .	3.1	3

#	Article	IF	Citations
91	Impact of comorbidities on the performance of interferon-gamma release assay in an elderly Greek population without overt immunodeficiency. International Journal of Antimicrobial Agents, 2020, 56, 106073.	2.5	1
92	Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa. Expert Opinion on Drug Safety, 2020, 19, 381-393.	2.4	8
93	Clinical efficacy of complement C5a inhibition by IFXâ€1 in hidradenitis suppurativa: an openâ€label singleâ€arm trial in patients not eligible for adalimumab. British Journal of Dermatology, 2020, 183, 176-178.	1.5	42
94	Staphylococcus Aureus Osteomyelitis as an Inducer of Tolerance to Escherichia Coli Pyelonephritis: an Experimental Study. Scientific Reports, 2020, 10, 1345.	3.3	1
95	Soluble urokinase plasminogen activator receptorÂ(suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Critical Care, 2020, 24, 187.	5.8	140
96	Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host and Microbe, 2020, 27, 992-1000.e3.	11.0	1,746
97	Effect of Triiodothyronine Administration on the Kidney During Haemorrhagic Shock and Resuscitation. Turkish Journal of Anaesthesiology and Reanimation, 2020, 48, 406-413.	0.4	0
98	Staphylococcus aureus and host interaction in the flareâ€ups of hidradenitis suppurativa. British Journal of Dermatology, 2019, 181, 892-893.	1.5	4
99	Susceptibility profiles and clinical efficacy of antifungals against candida bloodstream isolates from critically ill patients: Focus on intravenous itraconazole. International Journal of Antimicrobial Agents, 2019, 54, 471-477.	2.5	2
100	Microbiology of acute bacterial skin and skin-structure infections in Greece: A proposed clinical prediction score for the causative pathogen. International Journal of Antimicrobial Agents, 2019, 54, 750-756.	2.5	10
101	Current gaps in sepsis immunology: new opportunities for translational research. Lancet Infectious Diseases, The, 2019, 19, e422-e436.	9.1	205
102	Past history of stage I/II solid tumor malignancy impacts considerably on sepsis mortality: a propensity score matching analysis from the hellenic sepsis study group. BMC Infectious Diseases, 2019, 19, 831.	2.9	9
103	Identification of suitable controls for miRNA quantification in T-cells and whole blood cells in sepsis. Scientific Reports, 2019, 9, 15735.	3.3	11
104	Late Peaks of HMGB1 and Sepsis Outcome: Evidence For Synergy With Chronic Inflammatory Disorders. Shock, 2019, 52, 334-339.	2.1	21
105	Association of the early absolute CD64-expressing neutrophil count and sepsis outcome. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1123-1128.	2.9	5
106	Pharmacological management of sepsis in adults with a focus on the current gold standard treatments and promising adjunctive strategies: evidence from the last five years. Expert Opinion on Pharmacotherapy, 2019, 20, 991-1007.	1.8	5
107	The association between vegetation size and surgical treatment on 6-month mortality in left-sided infective endocarditis. European Heart Journal, 2019, 40, 2243-2251.	2.2	32
108	Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis. Frontiers in Immunology, 2019, 10, 55.	4.8	211

#	Article	IF	Citations
109	The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction. Journal of Investigative Dermatology, 2019, 139, 1294-1305.	0.7	153
110	The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: analysis through a derivation and a validation cohort. Critical Care, 2019, 23, 387.	5.8	63
111	Immunosuppression is Inappropriately Qualifying the Immune Status of Septic and SIRS Patients. Shock, 2019, 52, 307-317.	2.1	18
112	Association between genotypes of rs34436714 of NLRP12 and serum tumor necrosis factor-alpha in inflammatory bowel disease. Medicine (United States), 2019, 98, e15913.	1.0	2
113	Single nucleotide polymorphisms of Toll-like receptor-4 and of autophagy-related gene 16 like-1 gene for predisposition of premature delivery. Medicine (United States), 2019, 98, e17313.	1.0	5
114	An update on Staphylococcus aureus infective endocarditis from the International Society of Antimicrobial Chemotherapy (ISAC). International Journal of Antimicrobial Agents, 2019, 53, 9-15.	2.5	12
115	Costâ€savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a realâ€world cohort. British Journal of Dermatology, 2019, 180, 1161-1168.	1.5	15
116	Daptomycin as adjunctive treatment for experimental infection by Acinetobacter baumannii with resistance to colistin. International Journal of Antimicrobial Agents, 2019, 53, 190-194.	2.5	8
117	Early changes of the heatâ€shock protein 60 to 70 ratio as prediction of miscarriage in pregnancy. American Journal of Reproductive Immunology, 2019, 81, e13087.	1.2	7
118	Association between the timing of surgery for complicated, left-sided infective endocarditis and survival. American Heart Journal, 2019, 210, 108-116.	2.7	24
119	Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: Role of surgery and impact of colistin administration. International Journal of Antimicrobial Agents, 2019, 53, 294-301.	2.5	46
120	Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. Probiotics and Antimicrobial Proteins, 2019, 11, 627-634.	3.9	34
121	Immunomodulation in Sepsis and Infection. , 2019, , 533-544.		0
122	Reduced circulating B cells and plasma IgM levels are associated with decreased survival in sepsis - A meta-analysis. Journal of Critical Care, 2018, 45, 71-75.	2.2	34
123	Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection. JAMA - Journal of the American Medical Association, 2018, 319, 788.	7.4	236
124	Editorial Introduction to the Supplement "Diagnosis of Infectious Diseases by Detection of Microbial Pathogens: A Joint Session Between HemoSpec FrameWork 7 Consortium with COST Action BM1401 Raman4Clinics Working Group 2― Infectious Diseases and Therapy, 2018, 7, 1-2.	4.0	0
125	Transient Effects of Anesthesia on Leukocyte Apoptosis and Monocyte Cytokine Stimulation: A Clinical Study. Immunological Investigations, 2018, 47, 327-334.	2.0	5
126	Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?. British Journal of Dermatology, 2018, 179, 413-419.	1.5	60

#	Article	IF	CITATIONS
127	Haplotypes composed of minor frequency single nucleotide polymorphisms of the TNF gene protect from progression into sepsis: A study using the new sepsis classification. International Journal of Infectious Diseases, 2018, 67, 102-106.	3.3	11
128	MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study. Journal of Investigative Dermatology, 2018, 138, 795-801.	0.7	88
129	Increases in inflammatory and CD14dim/CD16pos/CD45pos patrolling monocytes in sepsis: correlation with final outcome. Critical Care, 2018, 22, 56.	5.8	32
130	Management of KPC-producing Klebsiella pneumoniae infections. Clinical Microbiology and Infection, 2018, 24, 133-144.	6.0	136
131	Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infectious Diseases and Therapy, 2018, 7, 439-455.	4.0	313
132	MicroRNAs 143 and 150 in whole blood enable detection of T-cell immunoparalysis in sepsis. Molecular Medicine, 2018, 24, 54.	4.4	33
133	Low-dose hydrocortisone prolongs survival in a lethal sepsis model in adrenalectomized rats. Journal of Surgical Research, 2018, 227, 72-80.	1.6	6
134	Progression into sepsis: an individualized process varying by the interaction of comorbidities with the underlying infection. BMC Infectious Diseases, 2018, 18, 242.	2.9	53
135	A prognostic score for the resolution of bacteremia by Gram-negative bacteria resistant to carbapenems. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 2083-2089.	2.9	2
136	Early increase of VEGFâ€A is associated with resolution of ventilatorâ€associated pneumonia: Clinical and experimental evidence. Respirology, 2018, 23, 942-949.	2.3	7
137	Three new case reports of Arteriovenous malformation-related Amyotrophic Lateral Sclerosis. Journal of the Neurological Sciences, 2018, 393, 58-62.	0.6	7
138	Dosing guidance for intravenous colistin in critically-ill patients. Clinical Infectious Diseases, 2017, 64, ciw839.	5.8	171
139	Is there a place for corticosteroids in the therapy of infective endocarditis? Report of a case and review. Hellenic Journal of Cardiology, 2017, 58, 93-95.	1.0	3
140	Increase of circulating endocan over sepsis follow-up is associated with progression into organ dysfunction. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 1749-1756.	2.9	30
141	Activation of NLRP3 Inflammasome in Inflammatory Bowel Disease: Differences Between Crohn's Disease and Ulcerative Colitis. Digestive Diseases and Sciences, 2017, 62, 2348-2356.	2.3	81
142	Efficacy of intramuscular moxifloxacin in the treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents, 2017, 50, 186-190.	2.5	11
143	The Not-So-Good Prognosis of Streptococcal Periprosthetic Joint Infection Managed by Implant Retention: The Results of a Large Multicenter Study. Clinical Infectious Diseases, 2017, 64, 1742-1752.	5.8	97
144	What is new in the management of skin and soft tissue infections in 2016?. Current Opinion in Infectious Diseases, 2017, 30, 158-171.	3.1	18

#	Article	IF	CITATIONS
145	Defective production of interleukin-1 beta in patients with type 2 diabetes mellitus: Restoration by proper glycemic control. Cytokine, 2017, 90, 177-184.	3.2	24
146	Platelet reactivity in sepsis syndrome: results from the PRESS study. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 2503-2512.	2.9	16
147	Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	60
148	A guiding map for inflammation. Nature Immunology, 2017, 18, 826-831.	14.5	506
149	The Statistical Significance of the Efficacy Results in a Randomized Clinical Trialâ€"Reply. JAMA Dermatology, 2017, 153, 950.	4.1	0
150	Development and validation of the International Hidradenitis Suppurativa Severity Score System () Tj ETQq0 0 0 Dermatology, 2017, 177, 1401-1409.	rgBT /Ove 1.5	rlock 10 Tf 50 301
151	Lipid peroxidation in Gram-negative bacteremia modulates the risk for septic shock and infections by resistant Klebsiella pneumoniae. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 2171-2177.	2.9	5
152	Reply to Corona and Cattaneo. Clinical Infectious Diseases, 2017, 65, 870-871.	5.8	4
153	Is small intestinal bacterial overgrowth involved in the pathogenesis of functional dyspepsia?. Medical Hypotheses, 2017, 106, 26-32.	1.5	23
154	Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. Critical Care, 2017, 21, 48.	5.8	29
155	Randomized, controlled, multicentre clinical trial of the antipyretic effect of intravenous paracetamol in patients admitted to hospital with infection. British Journal of Clinical Pharmacology, 2017, 83, 742-750.	2.4	8
156	Validation of the new Sepsis-3 definitions: proposal for improvement in early risk identification. Clinical Microbiology and Infection, 2017, 23, 104-109.	6.0	105
157	Survival after multiple traumas is associated with improved outcomes from gram-negative sepsis: Clinical and experimental evidence. Journal of Infection, 2017, 74, 163-171.	3.3	4
158	Spondylodiscitis revisited. EFORT Open Reviews, 2017, 2, 447-461.	4.1	56
159	Angiopoietin-2 Levels as Predictors of Outcome in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome. Disease Markers, 2017, 2017, 1-6.	1.3	18
160	Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Medicine, 2017, 15, 172.	5.5	132
161	Spondylitis transmitted from infected aortic grafts: a review. Journal of Bone and Joint Infection, 2017, 2, 96-103.	1.5	11
162	Pseudomonas oryzihabitans Infected Total Hip Arthroplasty. Journal of Bone and Joint Infection, 2016, 1, 54-58.	1.5	11

#	Article	IF	Citations
163	Sepsis: Diagnostic and Therapeutic Challenges. BioMed Research International, 2016, 2016, 1-2.	1.9	8
164	Soluble urokinase plasminogen activator receptor informs on the progression course after multiple injuries. Biomarkers, 2016, 21, 660-664.	1.9	8
165	High Copy Numbers of \hat{l}^2 -Defensin Cluster on 8p23.1, Confer Genetic Susceptibility, and Modulate the Physical Course of Hidradenitis Suppurativa/Acne Inversa. Journal of Investigative Dermatology, 2016, 136, 1592-1598.	0.7	42
166	Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. Antimicrobial Agents and Chemotherapy, 2016, 60, 3640-3646.	3.2	28
167	Systemic over-release of interleukin-17 in acute kidney injury after septic shock: Clinical and experimental evidence. Immunology Letters, 2016, 178, 68-76.	2.5	32
168	Methicillin-resistant Staphylococcus aureus infections: A review of the currently available treatment options. Journal of Global Antimicrobial Resistance, 2016, 7, 178-186.	2.2	87
169	Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage. BMC Gastroenterology, 2016, 16, 67.	2.0	37
170	Contemporary approaches to the rapid molecular diagnosis of sepsis. Expert Review of Molecular Diagnostics, 2016, 16, 1201-1207.	3.1	16
171	Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. New England Journal of Medicine, 2016, 375, 422-434.	27.0	530
172	Change of annexin binding of monocytes as an expression of cellular response to Candida albicans: down-regulation in severe sepsis. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 1787-1793.	2.9	1
173	Genetic Factors of the Disease Course After Sepsis: Rare Deleterious Variants Are Predictive. EBioMedicine, 2016, 12, 227-238.	6.1	34
174	Impact of patients' professional and educational status on perception of an antibiotic policy campaign: a pilot study at a university hospital. Journal of Global Antimicrobial Resistance, 2016, 6, 123-127.	2.2	11
175	A Transcriptomic Biomarker to Quantify Systemic Inflammation in Sepsis — A Prospective Multicenter Phase II Diagnostic Study. EBioMedicine, 2016, 6, 114-125.	6.1	53
176	Increased inÂvitro phenol-soluble modulin production is associated with soft tissue infection source in clinical isolates of methicillin-susceptible Staphylococcus aureus. Journal of Infection, 2016, 72, 302-308.	3.3	13
177	Individualized significance of the â^251 A/T single nucleotide polymorphism of interleukin-8 in severe infections. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 563-570.	2.9	13
178	Novel immunotherapeutic strategies for pyelonephritis. Immunotherapy, 2016, 8, 89-96.	2.0	0
179	Reverse kinetics of angiopoietin-2 and endotoxins in acute pyelonephritis: Implications for anti-inflammatory treatment?. Cytokine, 2016, 81, 28-34.	3.2	5
180	Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins. Clinical Microbiology and Infection, 2016, 22, 499-506.	6.0	38

#	Article	IF	Citations
181	Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nature Immunology, 2016, 17, 406-413.	14.5	437
182	Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?. Clinical Infectious Diseases, 2016, 62, 552-558.	5.8	145
183	Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa. JAMA Dermatology, 2016, 152, 52.	4.1	205
184	Polymorphisms of cystathionine beta-synthase gene are associated with susceptibility to sepsis. European Journal of Human Genetics, 2016, 24, 1041-1048.	2.8	8
185	When and how to operate on spondylodiscitis: a report of 13 patients. European Journal of Orthopaedic Surgery and Traumatology, 2016, 26, 31-40.	1.4	28
186	The role of genetics and antibodies in sepsis. Annals of Translational Medicine, 2016, 4, 328-328.	1.7	20
187	Can procalcitonin monitoring reduce the length of antibiotic treatment in bloodstream infections?. International Journal of Antimicrobial Agents, 2015, 46, S10-S12.	2.5	6
188	NK and NKT Cell Depletion Alters the Outcome of Experimental Pneumococcal Pneumonia: Relationship with Regulation of Interferon- $\langle i \rangle \hat{l}^3 \langle i \rangle$ Production. Journal of Immunology Research, 2015, 2015, 1-10.	2.2	26
189	The role of probiotics in the prevention of severe infections following abdominal surgery. International Journal of Antimicrobial Agents, 2015, 46, S2-S4.	2.5	7
190	suPAR: The unspecific marker for disease presence, severity and prognosis. International Journal of Antimicrobial Agents, 2015, 46, S33-S34.	2.5	43
191	Endogenous immunoglobulins and sepsis: New perspectives for guiding replacement therapies. International Journal of Antimicrobial Agents, 2015, 46, S25-S28.	2.5	29
192	Comparative efficacy of tigecycline VERSUS vancomycin in an experimental model of soft tissue infection by methicillin-resistant <i>Staphylococcus aureus</i> leukocidin. Journal of Chemotherapy, 2015, 27, 80-86.	1.5	3
193	Innate immunity alterations in idiopathic interstitial pneumonias and rheumatoid arthritis-associated interstitial lung diseases. Immunology Letters, 2015, 163, 179-186.	2.5	17
194	Immune responses in relation to the type and time of thermal injury: An experimental study. Injury, 2015, 46, 227-232.	1.7	9
195	Candida Infective Endocarditis: an Observational Cohort Study with a Focus on Therapy. Antimicrobial Agents and Chemotherapy, 2015, 59, 2365-2373.	3.2	68
196	Pre-treatment with probiotics prolongs survival after experimental infection by multidrug-resistant Pseudomonas aeruginosa in rodents: An effect on sepsis-induced immunosuppression. International Journal of Antimicrobial Agents, 2015, 45, 376-384.	2.5	19
197	Endotoxemia as a Diagnostic Tool for Patients with Suspected Bacteremia Caused by Gram-Negative Organisms: a Meta-Analysis of 4 Decades of Studies. Journal of Clinical Microbiology, 2015, 53, 1183-1191.	3.9	26
198	Esmolol: immunomodulator in pyelonephritis by Pseudomonas aeruginosa. Journal of Surgical Research, 2015, 198, 175-184.	1.6	4

#	Article	IF	Citations
199	Defective cytokine production early after multiple traumas: Modulation in severe sepsis. Cytokine, 2015, 76, 222-226.	3.2	16
200	Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. Scandinavian Journal of Gastroenterology, 2015, 50, 1076-1087.	1.5	85
201	A Fourâ€Probiotics Regimen Reduces Postoperative Complications After Colorectal Surgery: A Randomized, Doubleâ€Blind, Placeboâ€Controlled Study. World Journal of Surgery, 2015, 39, 2776-2783.	1.6	150
202	In Vitro Activity of Oral Cephalosporins (Cefprozil and Cefixime) Against Ciprofloxacin-Resistant Enterobacteriaceae from Community-Acquired Urinary-Tract Infections. Infectious Diseases and Therapy, 2015, 4, 425-432.	4.0	9
203	Response to Letter Regarding Article, "Association Between Surgical Indications, Operative Risk, and Clinical Outcome in Infective Endocarditis: A Prospective Study From the International Collaboration on Endocarditis― Circulation, 2015, 132, e184-5.	1.6	1
204	Comparison of brucellar and tuberculous spondylodiscitis patients: results of the multicenter "Backbone-1 Study― Spine Journal, 2015, 15, 2509-2517.	1.3	36
205	-572 G/C single nucleotide polymorphism of interleukin-6 and sepsis predisposition in chronic renal disease. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 2439-2446.	2.9	10
206	Interactions of Klebsiella pneumoniae with the Innate Immune System Vary in Relation to Clone and Resistance Phenotype. Antimicrobial Agents and Chemotherapy, 2015, 59, 7036-7043.	3.2	12
207	Impact of Early Valve Surgery on Outcome of Staphylococcus aureus Prosthetic Valve Infective Endocarditis: Analysis in the International Collaboration of Endocarditis–Prospective Cohort Study. Clinical Infectious Diseases, 2015, 60, 741-749.	5.8	84
208	Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma. Liver International, 2015, 35, 601-607.	3.9	35
209	Time–kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 317-323.	2.9	27
210	Host Response Biomarker in Sepsis: suPAR Detection. Methods in Molecular Biology, 2015, 1237, 241-246.	0.9	2
211	Compartmentalized Cytokine Responses in Hidradenitis Suppurativa. PLoS ONE, 2015, 10, e0130522.	2.5	57
212	Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome. Mini-Reviews in Medicinal Chemistry, 2015, 16, 186-192.	2.4	7
213	The complex pathogenesis of bacteremia. Virulence, 2014, 5, 57-65.	4.4	62
214	The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases. BMC Immunology, 2014, 15, 55.	2.2	54
215	Impact of TNF Haplotypes in the Physical Course of Acne Vulgaris. Dermatology, 2014, 228, 152-157.	2.1	16
216	Natural Killer Cells in Sepsis. Critical Care Medicine, 2014, 42, 1579-1580.	0.9	11

#	Article	IF	Citations
217	Obesity as a Consequence of Gut Bacteria and Diet Interactions. ISRN Obesity, 2014, 2014, 1-8.	2.2	41
218	Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. Nature Communications, 2014, 5, 4675.	12.8	76
219	Should we be moving from suppression to stimulation to deal with immunoparalysis in sepsis patients?. Immunotherapy, 2014, 6, 113-115.	2.0	1
220	Impact of haplotypes of TNF in the natural course of infective endocarditis. Clinical Microbiology and Infection, 2014, 20, 459-464.	6.0	11
221	Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by <i>Stenotrophomonas maltophilia</i> Immunology, 2014, 58, 96-102.	1.4	5
222	Proinflammatory cytokine responses in patients with psoriasis. European Cytokine Network, 2014, 25, 63-68.	2.0	34
223	Azithromycin: Mechanisms of action and their relevance for clinical applications., 2014, 143, 225-245.		448
224	In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. International Journal of Antimicrobial Agents, 2014, 43, 236-241.	2.5	41
225	The beginning of personalized medicine in sepsis: small steps to a bright future. Clinical Genetics, 2014, 86, 56-61.	2.0	54
226	Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2014, 69, 1111-1118.	3.0	46
227	Effect of clarithromycin in experimental empyema by multidrugâ€resistant <i>Pseudomonas aeruginosa</i> . Apmis, 2014, 122, 68-75.	2.0	3
228	Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science, 2014, 345, 1251086.	12.6	1,338
229	Differential role of NK cells against <i>Candida albicans</i> infection in immunocompetent or immunocompromised mice. European Journal of Immunology, 2014, 44, 2405-2414.	2.9	41
230	Association of autophagy-related 16-like 1 (ATG16L1) gene polymorphism with sepsis severity in patients with sepsis and ventilator-associated pneumonia. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 1609-1614.	2.9	21
231	The immunomodulatory and anti-apoptotic effect of dexamethasone in imminent preterm labor: An experimental study. European Journal of Pharmacology, 2014, 730, 31-35.	3.5	6
232	Bloodstream infections and sepsis in Greece: over-time change of epidemiology and impact of de-escalation on final outcome. BMC Infectious Diseases, 2014, 14, 272.	2.9	47
233	mTOR- and HIF-1α–mediated aerobic glycolysis as metabolic basis for trained immunity. Science, 2014, 345, 1250684.	12.6	1,517
234	Thalidomide prolongs survival after experimental musculoskeletal injury, through an effect on mononuclear apoptosis. Journal of Surgical Research, 2014, 188, 198-205.	1.6	2

#	Article	IF	CITATIONS
235	Immunomodulatory Intervention with Interferon- \hat{I}^3 in Escherichia coli Pyelonephritis. Journal of Urology, 2014, 192, 600-606.	0.4	10
236	Intravenous Paracetamol as an Antipyretic and Analgesic Medication: the Significance of Drug Metabolism. Journal of Pharmacological Sciences, 2014, 124, 144-152.	2.5	7
237	Angiopoietin-2 Primes Infection-Induced Preterm Delivery. PLoS ONE, 2014, 9, e86523.	2.5	9
238	Strontium ranelate improves delayed healing of osteolytic lesions of the jaw in a man with chronic osteomyelitis. Case report. Clinical Cases in Mineral and Bone Metabolism, 2014, 11, 77-81.	1.0	2
239	Circulating galectin-3 in infections and non-infectious inflammatory diseases. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1605-1610.	2.9	38
240	Introduction. International Journal of Antimicrobial Agents, 2013, 42, S1.	2.5	0
241	Differences in cytokine stimulation between methicillin-susceptible and methicillin-resistant Staphylococcus aureus in an experimental endocarditis model. Journal of Infection and Chemotherapy, 2013, 19, 272-278.	1.7	4
242	The Crystal Structure of Lipopolysaccharide Binding Protein Reveals the Location of a Frequent Mutation that Impairs Innate Immunity. Immunity, 2013, 39, 647-660.	14.3	102
243	Intravenous itraconazole against experimental neutropenic Candida parapsilosis infection: efficacy after suppression of bacterial translocation. Journal of Infection and Chemotherapy, 2013, 19, 1080-1086.	1.7	4
244	The functional role of natural killer cells early in clinical sepsis. Apmis, 2013, 121, 329-336.	2.0	17
245	An algorithm for the management of Staphylococcus aureus carriage within patients with recurrent staphylococcal skin infections. Journal of Infection and Chemotherapy, 2013, 19, 806-811.	1.7	12
246	Pulmonary nocardiosis in an immunocompetent patient with COPD: The role of defective innate response. Heart and Lung: Journal of Acute and Critical Care, 2013, 42, 247-250.	1.6	13
247	Aprikalim a potassium adenosine triphosphate channel opener reduces neurologic injury in a rabbit model of spinal cord ischemia. International Journal of Surgery, 2013, 11, 354-359.	2.7	3
248	The level of endotoxemia in sepsis varies in relation to the underlying infection: Impact on final outcome. Immunology Letters, 2013, 152, 167-172.	2.5	26
249	Function of blood monocytes among patients with orofacial infections. Journal of Cranio-Maxillo-Facial Surgery, 2013, 41, 88-91.	1.7	9
250	Bacterial translocation induces proinflammatory responsesÂand is associated with early death in experimental severe injury. Journal of Surgical Research, 2013, 185, 844-850.	1.6	4
251	Modulation of the release of Ang-2 in experimental endotoxic shock by a species-specific circulating factor. Injury, 2013, 44, 935-940.	1.7	4
252	Haplotypes of IL-12RÎ ² 1 impact on the clinical phenotype of hidradenitis suppurativa. Cytokine, 2013, 62, 297-301.	3.2	26

#	Article	IF	Citations
253	Impact of Toll-like receptor-4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa. British Journal of Dermatology, 2013, 168, 311-317.	1.5	44
254	Bacterial translocation in an experimental model of multiple organ dysfunctions. Journal of Surgical Research, 2013, 183, 686-694.	1.6	20
255	Pre-treatment with low-dose endotoxin prolongs survival from experimental lethal endotoxic shock: Benefit for lethal peritonitis by Escherichia coli. Cytokine, 2013, 62, 382-388.	3.2	22
256	Controversies in the management of the critically ill: the role of probiotics. International Journal of Antimicrobial Agents, 2013, 42, S41-S44.	2.5	37
257	Compartmentalization of lipid peroxidation in sepsis by multidrug-resistant gram-negative bacteria: experimental and clinical evidence. Critical Care, 2013, 17, R6.	5.8	20
258	The failure of biologics in sepsis: where do we stand?. International Journal of Antimicrobial Agents, 2013, 42, S45-S47.	2.5	9
259	Failure of treatments based on the cytokine storm theory of sepsis: time for a novel approach. Immunotherapy, 2013, 5, 207-209.	2.0	11
260	Alterations in the cellular component of the maternal immune system in a murine preterm delivery model. Journal of Maternal-Fetal and Neonatal Medicine, 2013, 26, 1024-1029.	1.5	9
261	Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome. Critical Care, 2013, 17, R247.	5.8	61
262	Dexamethasone Down-Regulates Expression of Triggering Receptor Expressed on Myeloid Cells-1: Evidence for a TNFα-Related Effect. Frontiers in Public Health, 2013, 1, 50.	2.7	8
263	Single nucleotide polymorphisms of tollâ€like receptorâ€4 protect against acne conglobata. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1538-1543.	2.4	9
264	Deficient Candida-Specific T-Helper 17 Response During Sepsis. Journal of Infectious Diseases, 2012, 206, 1798-1802.	4.0	15
265	Effect of Clarithromycin in Inflammatory Markers of Patients with Ventilator-Associated Pneumonia and Sepsis Caused by Gram-Negative Bacteria: Results from a Randomized Clinical Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 3819-3825.	3.2	57
266	Macrolides for the therapy of nosocomial infections. Current Opinion in Infectious Diseases, 2012, 25, 205-210.	3.1	8
267	The Control of Multidrug-Resistant Pseudomonas: Insights into Epidemiology and Management. , 2012, , 127-140.		0
268	Gene Polymorphisms in the Heme Degradation Pathway and Outcome of Severe Human Sepsis. Shock, 2012, 38, 459-465.	2.1	17
269	Angiopoietin-2 Enhances Survival in Experimental Sepsis Induced by Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 278-287.	2.5	19
270	Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Critical Care, 2012, 16, R149.	5.8	94

#	Article	IF	Citations
271	Candida albicans Infection Affords Protection against Reinfection via Functional Reprogramming of Monocytes. Cell Host and Microbe, 2012, 12, 223-232.	11.0	926
272	Role of tumor necrosis factor gene single nucleotide polymorphisms in the natural course of 2009 influenza A H1N1 virus infection. International Journal of Infectious Diseases, 2012, 16, e204-e208.	3.3	39
273	Emerging drugs for the treatment of sepsis. Expert Opinion on Emerging Drugs, 2012, 17, 379-391.	2.4	29
274	Genetic polymorphisms within tumor necrosis factor gene promoter region: A role for susceptibility to ventilator-associated pneumonia. Cytokine, 2012, 59, 358-363.	3.2	20
275	Molecular diagnosis of sepsis. Expert Opinion on Medical Diagnostics, 2012, 6, 209-219.	1.6	7
276	Probiotics for infectious diseases: more drugs, less dietary supplementation. International Journal of Antimicrobial Agents, 2012, 40, 288-296.	2.5	64
277	Association of Mal/TIRAP S180L variant polymorphism with decreased infection risk in patients with advanced HIV-1 infection. Cytokine, 2012, 60, 104-107.	3.2	5
278	The immune response to severe bacterial infections: consequences for therapy. Expert Review of Anti-Infective Therapy, 2012, 10, 369-380.	4.4	44
279	Enhanced interleukin- $1\hat{l}^2$ production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals. Arthritis Research and Therapy, 2012, 14, R158.	3.5	70
280	The Prevalence of Overgrowth by Aerobic Bacteria in the Small Intestine by Small Bowel Culture: Relationship with Irritable Bowel Syndrome. Digestive Diseases and Sciences, 2012, 57, 1321-1329.	2.3	159
281	Early serum levels of soluble triggering receptor expressed on myeloid cells–1 in septic patients: Correlation with monocyte gene expression. Journal of Critical Care, 2012, 27, 294-300.	2.2	26
282	Inhibition of caspase-1 activation in gram-negative sepsis and experimental endotoxemia. Critical Care, 2011, 15, R27.	5.8	61
283	Immunomodulation in sepsis: state of the art and future perspective. Immunotherapy, 2011, 3, 117-128.	2.0	23
284	Clarithromycin modulates immune responses in experimental peritonitis. International Journal of Antimicrobial Agents, 2011, 37, 347-351.	2.5	5
285	Changes in Adaptive and Innate Immunity in Patients with Acute Pancreatitis and Systemic Inflammatory Response Syndrome. Pancreatology, 2011, 11, 475-481.	1.1	24
286	Early increase of serum angiopoietin-2 are associated with early progression to death in experimental injury. Cytokine, 2011, 56, 817-822.	3.2	4
287	Angiopoietins in sepsis: Biomarkers or effector molecules?*. Critical Care Medicine, 2011, 39, 890-891.	0.9	2
288	Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. Journal of Critical Care, 2011, 26, 331.e1-331.e7.	2.2	44

#	Article	IF	Citations
289	Procalcitonin as an early indicator of outcome in sepsis: a prospective observational study. Journal of Hospital Infection, 2011, 77, 58-63.	2.9	45
290	Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. Journal of Infection, 2011, 63, 344-350.	3.3	65
291	Hypoxemic resuscitation from hemorrhagic shock prevents lung injury and attenuates oxidative response and IL-8 overexpression. Free Radical Biology and Medicine, 2011, 50, 245-253.	2.9	12
292	Serum sTREM-1 as a Surrogate Marker of Treatment Outcome in Patients with Peptic Ulcer Disease. Digestive Diseases and Sciences, 2011, 56, 3590-3595.	2.3	8
293	TREM-1 expression on neutrophils and monocytes of septic patients: relation to the underlying infection and the implicated pathogen. BMC Infectious Diseases, 2011, 11, 309.	2.9	17
294	Detrimental effect of apoptosis of lymphocytes at an early time point of experimental abdominal sepsis. BMC Infectious Diseases, 2011, 11, 321.	2.9	7
295	Serum kinetics of soluble triggering receptor expressed on myeloid cells-1 differs in relation to the type of arthroplasty. Biomarkers, 2011, 16, 600-604.	1.9	0
296	Efficacy of carbapenems against a metallo-Â-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model. Journal of Antimicrobial Chemotherapy, 2011, 66, 611-617.	3.0	20
297	Impact of Multidrug Resistance on Experimental Empyema by <i>Pseudomonas aeruginosa</i> Respiration, 2011, 82, 46-53.	2.6	8
298	Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. Journal of Antimicrobial Chemotherapy, 2011, 66, 1110-1116.	3.0	58
299	Experimental Osteomyelitis Caused by Methicillin-Resistant <i>Staphylococcus aureus</i> Treated with a Polylactide Carrier Releasing Linezolid. Surgical Infections, 2011, 12, 131-135.	1.4	9
300	Variation in Genes of \hat{l}^2 -glucan Recognition Pathway and Susceptibility to Opportunistic Infections in HIV-Positive Patients. Immunological Investigations, 2011, 40, 735-750.	2.0	7
301	Longâ€ŧerm efficacy of etanercept in hidradenitis suppurativa: results from an openâ€label phase II prospective trial. Experimental Dermatology, 2010, 19, 538-540.	2.9	43
302	<i>In vitro</i> elution of moxifloxacin from cancellous bone allografts. Journal of Biomedical Materials Research - Part A, 2010, 92A, 52-55.	4.0	4
303	Engagement of fatty acids with tollâ€like receptor 2 drives interleukinâ€lβ production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal–induced gouty arthritis. Arthritis and Rheumatism, 2010, 62, 3237-3248.	6.7	259
304	Diagnostic value of triggering receptor expressed on myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational study. BMC Infectious Diseases, 2010, 10, 286.	2.9	22
305	Ultrasound aids in diagnosis and severity assessment of hidradenitis suppurativa. British Journal of Dermatology, 2010, 162, 1400-1402.	1.5	44
306	Indication for a role of regulatory T cells for the advent of influenza A (H1N1)-related pneumonia. Clinical and Experimental Immunology, 2010, 161, 576-583.	2.6	6

#	Article	IF	CITATIONS
307	Association of Tollâ€Like Receptor 4 Asp299Gly and Thr399lle Polymorphisms with Increased Infection Risk in Patients with Advanced HIVâ€I Infection. Clinical Infectious Diseases, 2010, 51, 242-247.	5.8	29
308	Use of Oleuropein in Experimental Sepsis by Pseudomonas Aeruginosa. , 2010, , 1321-1325.		0
309	Macrocycle Molecules for the Management of Systemic Infections: the Clarithromycin Paradigm. Current Topics in Medicinal Chemistry, 2010, 10, 1470-1475.	2.1	5
310	Impact of synbiotics on the intestinal flora of critically ill patients with multiple injuries. International Journal of Antimicrobial Agents, 2010, 36, 90-91.	2.5	21
311	Post-antibiotic effect (PAE) of moxifloxacin in multidrug-resistant Stenotrophomonas maltophilia. International Journal of Antimicrobial Agents, 2010, 36, 387-389.	2.5	4
312	Introduction. International Journal of Antimicrobial Agents, 2010, 36, S1.	2.5	3
313	What is the pathophysiology of the septic host upon admission?. International Journal of Antimicrobial Agents, 2010, 36, S2-S5.	2.5	25
314	Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Critical Care, 2010, 14, R96.	5.8	109
315	Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: an observational study in three cohorts. Critical Care, 2010, 14, R103.	5.8	72
316	Adipocyte factors, high-sensitive C-reactive protein levels and lipoxidative stress products in overweight postmenopausal women with normal and impaired OGTT. Maturitas, 2010, 67, 72-77.	2.4	26
317	Εx-vivo effect of dexamethasone on cytokine production from whole blood of septic patients: Correlation with disease severity. Cytokine, 2010, 49, 89-94.	3.2	12
318	Eicosapentanoic acid prolongs survival and attenuates inflammatory response in an experimental model of lethal trauma. Prostaglandins Leukotrienes and Essential Fatty Acids, 2010, 83, 69-74.	2.2	2
319	An early circulating factor in severe sepsis modulates apoptosis of monocytes and lymphocytes. Journal of Leukocyte Biology, 2010, 89, 343-349.	3.3	24
320	Hidradenitis suppurativa as a chronic inflammatory disorder: are biological therapies the future therapeutic solution?. Expert Review of Dermatology, 2009, 4, 47-54.	0.3	0
321	Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10272-10277.	7.1	87
322	Clinical Consensus Conference: Survey on Gramâ€Positive Bloodstream Infections with a Focus onStaphylococcus aureus. Clinical Infectious Diseases, 2009, 48, S260-S270.	5.8	39
323	Pro- and Synbiotics to Control Inflammation and Infection in Patients With Multiple Injuries. Journal of Trauma, 2009, 67, 815-821.	2.3	94
324	In Vitro Elution of Daptomycin by a Synthetic Crystallic Semihydrate Form of Calcium Sulfate, Stimulan. Antimicrobial Agents and Chemotherapy, 2009, 53, 3106-3107.	3.2	26

#	Article	IF	CITATIONS
325	Serum of patients with septic shock stimulates the expression of Trem-1 on U937 monocytes. Inflammation Research, 2009, 58, 127-132.	4.0	15
326	Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infectious Diseases, 2009, 9, 213.	2.9	47
327	Implications for a role of interleukin-23 in the pathogenesis of chronic gastritis and of peptic ulcer disease. Clinical and Experimental Immunology, 2009, 156, 97-101.	2.6	14
328	Angiopoietin-2 is increased in septic shock: Evidence for the existence of a circulating factor stimulating its release from human monocytes. Immunology Letters, 2009, 125, 65-71.	2.5	44
329	Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin $1\hat{1}^2$ by mononuclear cells through a caspase 1-mediated process. Annals of the Rheumatic Diseases, 2009, 68, 273-278.	0.9	111
330	Decrease of CD4-lymphocytes and apoptosis of CD14-monocytes are characteristic alterations in sepsis caused by ventilator-associated pneumonia: results from an observational study. Critical Care, 2009, 13, R172.	5. 8	34
331	Hypoxemic resuscitation after hemorrhagic shock is accompanied by reduced serum levels of angiopoietin-2. Cytokine, 2009, 47, 82-84.	3.2	5
332	Cerebrospinal fluid of patients administered moxifloxacin modulates the secretion of cytokines from human monocytes. Diagnostic Microbiology and Infectious Disease, 2009, 63, 62-69.	1.8	3
333	Does a bed rail system of alcohol-based handrub antiseptic improve compliance of health care workers with hand hygiene? Results from a pilot study. American Journal of Infection Control, 2009, 37, 160-163.	2.3	17
334	Pharmacokinetics of intravenously administered moxifloxacin in eye compartments: an experimental study. International Journal of Antimicrobial Agents, 2009, 33, 160-162.	2.5	7
335	Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a synthetic carrier of calcium sulphate (Stimulan \hat{A}^{o}) releasing moxifloxacin. International Journal of Antimicrobial Agents, 2009, 33, 354-359.	2.5	60
336	Efficacy of teicoplanin for the prevention of surgical site infections after total hip or knee arthroplasty: a prospective, open-label study. International Journal of Antimicrobial Agents, 2009, 33, 437-440.	2.5	28
337	Short-Term Administration of a High Oxygen Concentration Is Not Injurious in an Ex-Vivo Rabbit Model of Ventilator-Induced Lung Injury. Anesthesia and Analgesia, 2009, 108, 556-564.	2.2	8
338	Clarithromycin: A Promising Immunomodulator in Sepsis. , 2009, , 111-118.		1
339	Effect of the Novel Influenza A (H1N1) Virus in the Human Immune System. PLoS ONE, 2009, 4, e8393.	2.5	62
340	An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. British Journal of Dermatology, 2008, 158, 567-572.	1.5	109
341	The level of hypotension during hemorrhagic shock is a major determinant of the post-resuscitation systemic inflammatory response: an experimental study. BMC Physiology, 2008, 8, 15.	3.6	20
342	What causes hidradenitis suppurativa?. Experimental Dermatology, 2008, 17, 455-456.	2.9	243

#	Article	IF	Citations
343	The impact of multidrug resistance on the pathogenicity of Escherichia coli: an experimental study. International Journal of Antimicrobial Agents, 2008, 31, 216-223.	2.5	10
344	Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. International Journal of Antimicrobial Agents, 2008, 32, 46-49.	2.5	17
345	In vitro synergism of \hat{l}^2 -lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2008, 32, 33-39.	2.5	17
346	Immunomodulatory therapies for sepsis: unexpected effects with macrolides. International Journal of Antimicrobial Agents, 2008, 32, S39-S43.	2.5	38
347	Kinetics of Angiopoietin-2 in serum of multi-trauma patients: Correlation with patient severity. Cytokine, 2008, 44, 310-313.	3.2	36
348	Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. International Journal of Antimicrobial Agents, 2008, 31, 12-20.	2.5	165
349	Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. Journal of Antimicrobial Chemotherapy, 2008, 61, 1328-1331.	3.0	47
350	Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis. Journal of Antimicrobial Chemotherapy, 2008, 62, 381-383.	3.0	29
351	Local Treatment of Experimental Pseudomonas aeruginosa Osteomyelitis with a Biodegradable Dilactide Polymer Releasing Ciprofloxacin. Antimicrobial Agents and Chemotherapy, 2008, 52, 2335-2339.	3.2	19
352	The Importance of Fever as a Predictive Symptom for the Potency of Host's Monocytes to Release Proand Anti-Inflammatory Mediators. Mediators of Inflammation, 2008, 2008, 1-7.	3.0	2
353	Effect of Clarithromycin in Patients with Sepsis and Ventilatorâ€Associated Pneumonia. Clinical Infectious Diseases, 2008, 46, 1157-1164.	5.8	227
354	Evaluation of the Effects of Laparotomy and Laparoscopy on the Immune System in Intra-Abdominal Sepsis—A Review. Journal of Investigative Surgery, 2008, 21, 330-339.	1.3	26
355	Evidence for the Participation of Soluble Triggering Receptor Expressed on Myeloid Cells-1 in the Systemic Inflammatory Response Syndrome After Multiple Trauma. Journal of Trauma, 2008, 65, 1385-1390.	2.3	23
356	What causes hidradenitis suppurativa?. Experimental Dermatology, 2008, 17, 455-472.	2.9	226
357	<i>TLR4</i> polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16645-16650.	7.1	293
358	Tumour necrosis factor-alpha (TNF $\hat{l}\pm$) and interleukin-10 are crucial mediators in post-operative systemic inflammatory response and determine the occurrence of complications after major abdominal surgery. Cytokine, 2007, 37, 55-61.	3.2	51
359	In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii. Diagnostic Microbiology and Infectious Disease, 2007, 57, 419-422.	1.8	32
360	Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. International Journal of Antimicrobial Agents, 2007, 29, 51-55.	2.5	77

#	Article	IF	Citations
361	The significance of compliance for the success of antimicrobial prophylaxis in recurrent lower urinary tract infections: the Greek experience. International Journal of Antimicrobial Agents, 2007, 30, 40-43.	2.5	13
362	Grouping of patients with common variable immunodeficiency based on immunoglobulin biosynthesis: Comparison with a classification system on CD4-naÃ-ve cells. Immunology Letters, 2007, 114, 103-109.	2.5	7
363	Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. British Journal of Dermatology, 2007, 156, 51-56.	1.5	118
364	Early apoptosis of blood monocytes is a determinant of survival in experimental sepsis by multi-drug-resistant <i>Pseudomonas aeruginosa</i> . Clinical and Experimental Immunology, 2007, 149, 103-108.	2.6	11
365	Stimulation of monocytes is a pathway involved in systemic inflammatory response following haemorrhagic shock resuscitation: the effect of hypoxaemic resuscitation. Clinical and Experimental Immunology, 2007, 150, 502-508.	2.6	8
366	Defining duplicate publication: reply to H.†F. Galley. Intensive Care Medicine, 2007, 33, 373-373.	8.2	1
367	Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Medicine, 2007, 33, 1524-1532.	8.2	7 5
368	Can Soluble Triggering Receptor Expressed on Myeloid Cells (sTREM-1) Be Considered an Anti-Inflammatory Mediator in the Pathogenesis of Peptic Ulcer Disease?. Digestive Diseases and Sciences, 2007, 52, 2166-2169.	2.3	10
369	Monocytes as a site of production of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in the septic host. Scandinavian Journal of Infectious Diseases, 2006, 38, 909-915.	1.5	3
370	Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. International Journal of Antimicrobial Agents, 2006, 27, 476-481.	2.5	44
371	Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock?. Critical Care, 2006, 10, R76.	5.8	47
372	Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis. Critical Care, 2006, 10, R166.	5.8	67
373	An update on the etiology and diagnostic evaluation of a leukemoid reaction. European Journal of Internal Medicine, 2006, 17, 394-398.	2.2	94
374	Portal and Systemic Endotoxemia in Abdominal Operations: The Significance of Acute Abdomen. Journal of Surgical Research, 2006, 134, 133-137.	1.6	7
375	Is There Any Role for Innate Immunity in the Pathogenesis of Bacterial and Abacterial Meningitis?. Infectious Diseases in Clinical Practice, 2006, 14, 17-22.	0.3	0
376	Soluble triggering receptor expressed on myeloid cells (sTREM-1): a new mediator involved in the pathogenesis of peptic ulcer disease. European Journal of Gastroenterology and Hepatology, 2006, 18, 375-379.	1.6	38
377	OLEUROPEIN. Shock, 2006, 26, 410-416.	2.1	37
378	The Effect of Hypoxemic Resuscitation of Hemorrhagic Shock on Hemodynamic Stabilization and Inflammatory Response: A Pilot Study in a Rat Experimental Model. Journal of Trauma, 2006, 61, 918-923.	2.3	10

#	Article	IF	CITATIONS
379	Kinetics of progenitor hemopoetic stem cells in sepsis: Correlation with patients survival?. BMC Infectious Diseases, 2006, 6, 142.	2.9	18
380	Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa. BMC Infectious Diseases, 2006, 6, 31.	2.9	24
381	Early apoptosis of monocytes contributes to the pathogenesis of systemic inflammatory response and of bacterial translocation in an experimental model of multiple trauma. Clinical and Experimental Immunology, 2006, 145, 139-146.	2.6	16
382	Soluble triggering receptor expressed on myeloid cells 1 as an anti-inflammatory mediator in sepsis. Intensive Care Medicine, 2006, 32, 237-243.	8.2	72
383	Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2006, 57, 937-944.	3.0	44
384	Does soluble triggering receptor expressed on myeloid cells-1 play any role in the pathogenesis of septic shock?. Clinical and Experimental Immunology, 2005, 142, 62-67.	2.6	49
385	Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study. BMC Infectious Diseases, 2005, 5, 51.	2.9	16
386	Penetration of Clarithromycin in Experimental Pleural Empyema Model Fluid. Respiration, 2005, 72, 296-300.	2.6	15
387	Septic arthritis due to Salmonella enteritidis associated with infliximab use. Scandinavian Journal of Infectious Diseases, 2005, 37, 304-306.	1.5	45
388	Clarithromycin: Immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. Scandinavian Journal of Infectious Diseases, 2005, 37, 48-54.	1.5	24
389	Postantibiotic effect of antimicrobial combinations on multidrug-resistant Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease, 2005, 51, 113-117.	1.8	23
390	The significance of oxidant/antioxidant balance for the pathogenesis of experimental sepsis by multidrug-resistant Pseudomonas aeruginosa. Prostaglandins Leukotrienes and Essential Fatty Acids, 2005, 72, 41-47.	2.2	4
391	N-6 polynsaturated fatty acids confer hemodynamic stability in an experimental model of multiple trauma. Prostaglandins Leukotrienes and Essential Fatty Acids, 2005, 72, 357-362.	2.2	5
392	Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli. International Journal of Antimicrobial Agents, 2005, 25, 168-172.	2.5	30
393	Immunomodulatory Clarithromycin Treatment of Experimental Sepsis and Acute Pyelonephritis Caused by Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . Antimicrobial Agents and Chemotherapy, 2004, 48, 93-99.	3.2	78
394	n-6 Polyunsaturated Fatty Acids Enhance the Activities of Ceftazidime and Amikacin in Experimental Sepsis Caused by Multidrug-Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2004, 48, 4713-4717.	3.2	19
395	Early Cutaneous Alterations in Experimental Sepsis by <i>Pseudomonas aeruginosa</i> 2004, 209, 111-116.	2.1	2
396	Stimulation of innate immunity by susceptible and multidrug-resistant <i>Pseudomonas aeruginosa</i> : an <i>in vitro</i> and <i>in vivo</i> study. Clinical and Experimental Immunology, 2004, 135, 240-246.	2.6	41

#	Article	IF	CITATIONS
397	Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clinical Microbiology and Infection, 2004, 10, 628-633.	6.0	76
398	Should procalcitonin be introduced in the diagnostic criteria for the systemic inflammatory response syndrome and sepsis?. Journal of Critical Care, 2004, 19, 152-157.	2.2	51
399	Pharmacokinetic interactions of ceftazidime, imipenem and aztreonam with amikacin in healthy volunteers. International Journal of Antimicrobial Agents, 2004, 23, 144-149.	2.5	23
400	The influence of indomethacin co-administration on ofloxacin levels in plasma and cerebrospinal fluid in rats. International Journal of Antimicrobial Agents, 2004, 23, 371-376.	2.5	2
401	Experimental sepsis using Pseudomonas aeruginosa: the significance of multi-drug resistance. International Journal of Antimicrobial Agents, 2004, 24, 357-361.	2.5	17
402	Rapid alterations of serum fatty acids with the intravenous administration of an arachidonate solution. Prostaglandins Leukotrienes and Essential Fatty Acids, 2004, 70, 465-468.	2.2	4
403	Lipid peroxidation and inguinal hernia repair. Tension-free vs. Andrews technique. Prostaglandins Leukotrienes and Essential Fatty Acids, 2004, 71, 221-225.	2.2	3
404	Alterations of systemic endotoxemia over the course of acute edematous pancreatitis. Pancreatology, 2003, 3, 323-328.	1.1	6
405	Pneumocystis carinii Pneumonia in an Immunocompetent Host. Clinical Drug Investigation, 2003, 23, 135-137.	2.2	O
406	Systemic endotoxaemia following obstructive jaundice: the role of lactulose. Journal of Surgical Research, 2003, 113, 243-247.	1.6	29
407	Lipid peroxidation in chronic gastritis; any influence of Helicobacter pylori?. Prostaglandins Leukotrienes and Essential Fatty Acids, 2003, 68, 257-261.	2.2	10
408	Ex vivo synergy of arachidonate-enriched serum with ceftazidime and amikacin on multidrug-resistant Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2003, 51, 423-426.	3.0	4
409	Effective Immunomodulatory Treatment of Escherichia coli Experimental Sepsis with Thalidomide. Antimicrobial Agents and Chemotherapy, 2003, 47, 2445-2449.	3.2	15
410	Antimicrobial-induced endotoxaemia in patients with sepsis in the field of acute pyelonephritis. Journal of Postgraduate Medicine, 2003, 49, 118-22.	0.4	3
411	In Vitro Killing Effect of Moxifloxacin on Clinical Isolates of Stenotrophomonas maltophilia Resistant to Trimethoprim-Sulfamethoxazole. Antimicrobial Agents and Chemotherapy, 2002, 46, 3997-3999.	3.2	20
412	Pharmacokinetics of teicoplanin in patients undergoing chronic haemodialysis. International Journal of Antimicrobial Agents, 2002, 19, 233-236.	2.5	17
413	Bacterial translocation following intrabdominal surgery. Any influence of antimicrobial prophylaxis?. International Journal of Antimicrobial Agents, 2002, 20, 457-460.	2.5	21
414	Rapid alterations of serum oxidant and antioxidant status with the intravenous administration of n-6 polyunsaturated fatty acids. Prostaglandins Leukotrienes and Essential Fatty Acids, 2002, 67, 57-62.	2.2	8

#	Article	IF	Citations
415	Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagnostic Microbiology and Infectious Disease, 2002, 44, 259-263.	1.8	52
416	Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient?. Intensive Care Medicine, 2002, 28, 1351-1356.	8.2	137
417	Primary meningococcal arthritis: case report and review. Clinical and Experimental Rheumatology, 2002, 20, 553-4.	0.8	14
418	Pharmacokinetics of intravenously administered pefloxacin in the prostate; perspectives for its application in surgical prophylaxis. International Journal of Antimicrobial Agents, 2001, 17, 221-224.	2.5	3
419	Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. International Journal of Antimicrobial Agents, 2001, 18, 441-444.	2.5	16
420	Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagnostic Microbiology and Infectious Disease, 2001, 40, 117-120.	1.8	124
421	PHARMACOKINETICS OF CLARITHROMYCIN IN THE PROSTATE: IMPLICATIONS FOR THE TREATMENT OF CHRONIC ABACTERIAL PROSTATITIS. Journal of Urology, 2001, 165, 97-99.	0.4	18
422	In Vitro Activities of Ertapenem (MK-0826) against Recent Clinical Bacteria Collected in Europe and Australia. Antimicrobial Agents and Chemotherapy, 2001, 45, 1860-1867.	3.2	122
423	Assessment of Procalcitonin as a Diagnostic Marker of Underlying Infection in Patients with Febrile Neutropenia. Clinical Infectious Diseases, 2001, 32, 1718-1725.	5.8	94
424	Impact of n-6 Polyunsaturated Fatty Acids on Growth of Multidrug-Resistant Pseudomonas aeruginosa: Interactions with Amikacin and Ceftazidime. Antimicrobial Agents and Chemotherapy, 2000, 44, 2187-2189.	3.2	17
425	Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a biodegradable system of lactic acid polymer releasing pefloxacin. Journal of Antimicrobial Chemotherapy, 2000, 46, 311-314.	3.0	39
426	In-vitro activity of FK 037 (Cefoselis), a novel 4th generation Cephalosporin, compared to Cefepime and Cefpirome on nosocomial staphylococci and gram-negative isolatesâ~†. Diagnostic Microbiology and Infectious Disease, 2000, 36, 185-191.	1.8	13
427	Comparative Postantibiotic Effect of Sitafloxacin and Trovafloxacin on Methicillin-Resistant Staphylococcus aureus. Drugs, 1999, 58, 146-148.	10.9	1
428	In vitro activity of polyunsaturated fatty acids on Pseudomonas aeruginosa: relationship to lipid peroxidation. Prostaglandins Leukotrienes and Essential Fatty Acids, 1998, 58, 283-287.	2.2	29
429	Interactions of Ceftazidime and Amikacin on Multiresistant Pseudomonas aeruginosa. Clinical Drug Investigation, 1998, 16, 167-171.	2.2	1
430	In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates. Journal of Antimicrobial Chemotherapy, 1998, 41, 349-355.	3.0	27
431	In Vitro Activity of Quinupristin/Dalfopristin and Newer Quinolones Combined with Gentamicin against Resistant Isolates of Enterococcus faecalis and Enterococcus faecium. European Journal of Clinical Microbiology and Infectious Diseases, 1998, 17, 657-661.	2.9	4
432	Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease, 1997, 29, 81-86.	1.8	27

Evangelos J

#	Article	IF	CITATIONS
433	In vitro activity and killing effect of DX-8739, a new carbapenem, compared with those of meropenem and imipenem against multiresistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 1995, 39, 731-734.	3.2	3
434	In vitro influence of polyunsaturated fatty acids on nosocomial Pseudomonas aeruginosa: a preliminary report. International Journal of Antimicrobial Agents, 1995, 6, 47-50.	2.5	5
435	Single-Nucleotide Polymorphisms and Inflammation. , 0, , 1329-1346.		O